Junction: Idiopathic Pulmonary Fibrosis

Second-Line Antifibrotic Treatment May Improve Management of IPF

Switching antifibrotic drugs could improve the treatment of patients with idiopathic pulmonary fibrosis (IPF) who develop intolerable adverse effects or show disease progression after first-line antifibrotic treatment, according to a multicenter study conducted in Turkey. The authors of the study recently published in the journal Pulmonary Pharmacology & Therapeutics showed that forced vital capacity (FVC)…

Key Biomarkers Identified in IPF Could Predict Prognosis

A panel of molecules identified by a team of researchers might be useful for improving the diagnosis and management of idiopathic pulmonary fibrosis (IPF). “We have presented a unique comparative transcriptome-proteome signature of advanced IPF and identified key tissue and circulating biomarkers that could be predictive of progressive/worsening IPF,” said Sivakumar and colleagues, from Bristol-Myers…

Aging-Associated Genes May Impact Idiopathic Pulmonary Fibrosis

Researchers identified 4 aging-associated genes that might be involved in the development of pulmonary fibrosis. The genes were identified through data mining of gene expression profiles from patients with idiopathic pulmonary fibrosis (IPF) and a mouse model with bleomycin-induced pulmonary fibrosis (BIPF). “Aging is a strong risk factor and an independent prognostic biomarker for progressive…

DCE-MRI Can Have Therapeutic Value for Patients With IPF

A team of researchers discovered that dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) can be used to detect changes in the microvasculature and extravascular extracellular space of the lungs in patients with idiopathic pulmonary fibrosis (IPF). The new study was published in ERJ Open Research. Medical literature suggests IPF is associated with pulmonary circulatory abnormalities that…

Hypothyroidism Shown to Have Causal Effect on Idiopathic Pulmonary Fibrosis

Hypothyroidism has a positive causal effect on idiopathic pulmonary fibrosis (IPF), according to a new study by Chinese researchers. “These findings may have an important insight into pathogenesis and possible future therapies of IPF,” the authors wrote in the study, which appeared in EBioMedicine published by The Lancet. Observational studies have already shown an association…

human lung

New Approach Could Block Fibrogenesis in IPF

Dual inhibition of integrin alpha-v beta-6 (αvβ6) and integrin alpha-v beta-1 (αvβ1) showed an additive effect in reducing collagen expression in lung explant cultures from patients with idiopathic pulmonary fibrosis (IPF), according to a new study published in Respiratory Research. “Using a well-characterized set of small-molecule and antibody-based integrin inhibitors, we evaluated multiple αv integrin inhibition…

Newly Developed Multiplex Network Could Improve Rare Disease Research

Researchers in Austria developed a multiplex network by mapping genes and their interactions on multiple levels, which can help better identify genetic defects and study their consequences.  To build the network, the team led by Jörg Menche, PhD, adjunct principal investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences…

Next post in IPF Insights